KetaMD, a Telemedicine for At-Home Ketamine Treatments, Acquired by Braxia Scientific Corp.

KetaMD, a Florida-based telemedicine company providing access to at-home ketamine treatments for people suffering from depression and related mental health conditions, has been acquired by Toronto-based Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders. With this recent acquisition, KetaMD is now available in the State of Florida with a rollout to other key states planned next year.

KetaMD's end-to-end telemedicine platform, utilizing leading technology and a mobile app, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions. Treatments are medically supervised, guided virtually by registered nurses, and backed by the world's leading psychiatrists and researchers in depression.

Braxia Scientific plans to further augment the KetaMD platform, including planning new clinical trials in the U.S. and leveraging Braxia's growing proprietary patient dataset, to support the potential future development of psychedelic therapeutics in the management of depression and other related mental health conditions. KetaMD's innovative technology capabilities provide Braxia the opportunity to offer both in-person and digital telehealth ketamine treatments, combined with established clinical research and development capabilities focused on the commercialization and real-world implementation of novel pharmaceuticals.

"The KetaMD team is honored to have the opportunity to work with Braxia CEO Dr. McIntyre and a world-leading research team at Braxia Scientific in the area of depression and mood disorders,” said Warren Gumpel, CEO and Co-Founder of KetaMD. “I believe this will be the key distinguishing factor in KetaMD's success."

"This acquisition is a notable step forward in bringing awareness, accessibility, and scalability of the benefits of ketamine and psychedelics generally for those suffering from depression and other mood disorders," said Dr. Roger McIntyre, CEO, Braxia Scientific. "We've seen improved outcomes firsthand from ketamine treatment in our clinics and in our clinical trials. Adding digital telehealth capabilities through KetaMD's online and mobile platform strengthens our position to lead the medical use of evidence-based psychedelics, while accelerating our ability to get treatment to those in need, safely and quickly across the U.S. and Canada, and globally in the future."

KetaMD was founded by psychedelic pioneers Zappy Zapolin and Warren Gumpel, along with mindfulness instructor and brand experience expert Kaia Roman and the company's President and Chief Operating Officer, Leann Taylor. The team are dedicated to helping those suffering from debilitating mental health issues find relief through ketamine and other novel psychedelic medicines.

For those interested in qualifying for KetaMD are encouraged to visit www.KetaMD.com and download the KetaMD app.

By ML Staff. Image by KetaMD.